Memory Biomarkers Confirm Aerobic Exercise Helps Cognitive Function in Older Adults

Until now, systemic biomarkers to measure exercise effects on brain function and that link to relevant metabolic responses were lacking. A study shows a memory biomarker, myokine Cathepsin B (CTSB), increased in older adults following a 26-week structured aerobic exercise training. The positive association between CTSB and cognition, and the substantial modulation of lipid metabolites implicated in dementia, support the beneficial effects of exercise training on brain function and brain health in asymptomatic individuals at risk for Alzheimer’s.

Study Identifies Never-Before-Seen Dual Function in Enzyme Critical for Cancer Growth

In developing therapies for hard-to-treat breast and ovarian cancers in patients with BRCA gene mutations, scientists aim to identify ways to keep cancer cells from using DNA break repair pathways. New findings demonstrate a previously-unknown capability for polymerase theta (pol theta) – a key enzyme in this repair function – that shows promise as a new avenue for treatment development.

NYU, Columbia, and Takeda Form Research Alliance for Gastrointestinal and Liver Disorders

New York University, Columbia University, and Takeda Pharmaceutical Company Limited (“Takeda”) have formed a collaborative research alliance to begin and advance gastroenterology research programs, with the goal of developing new therapies for patients with gastrointestinal and liver disorders.

Guilt by Dissociation: Study Sheds Light on Serotonin in Autism

A study on serotonin, a mood-regulating molecule in the brain that regulates many brain synapses, is helping to unravel the puzzle surrounding its role in autism. The activity and regulation of the serotonin transporter (SERT), protein is critically dependent on a number of other proteins that tell the protein where to locate on nerve cells and how to act. Shifts in the transporter’s activity can significantly impact the ability of serotonin to act in the brain.

New Treatment Developed by Children’s Hospital of Philadelphia Shows Success in High-Risk Solid Tumors

In a breakthrough study, researchers at Children’s Hospital of Philadelphia (CHOP) have shown that an enhanced treatment developed in their lab leads to long-term remissions in 80% to 100% of mice with drug-resistant or high-risk solid tumors. The research, which could soon lead to clinical trials, is described in Cancer Research, a journal of the American Association for Cancer Research.

Ready to Join the Fight Against COVID-19

UPTON, NY—On July 29, 2020 the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory opened a new cryo-electron microscopy center, the Laboratory for BioMolecular Structure (LBMS), with an initial focus on COVID-19-related research. This state-of-the-art research center for life sciences imaging offers researchers access to advanced cryo-electron microscopes (cryo-EM)—funded by NY State—for studying complex proteins, as well as the architecture of cells and tissues.

A New Approach to Tailoring Cancer Therapy: Tapping Into Signaling Activities in Cancer Cells

The Weizmann Institute’s Dr. Ravid Straussman and colleagues developed a method that utilizes cellular signaling to determine the best treatment for a given tumor. The method can help tailor treatments and identify new drug-development targets. In fact, the team has already singled out a gene that serves as a target for treating BRCA-related breast cancers.

Memorial Sloan Kettering Awards and Appointments

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

UTEP Research Reveals More About Path Bacterial Pathogen Travels to Cause Tuberculosis

Jianjun Sun, Ph.D., associate professor in UTEP’s Department of Biological Sciences, led the research on Mycobacterium tuberculosis (Mtb). Sun’s lab has been investigating the mechanisms of Mtb pathogenesis for more than 10 years at UTEP with a specific focus on EsxA, which is a virulence factor essential for Mtb virulence and a preferred target for developing novel anti-TB drugs and vaccines.

‘Rushed’ Drug Development that Aims to Refill Pharma Firms’ Pipelines Is Less Likely to Succeed Because of Inter-organizational Friction

When a large pharmaceutical company experiences a drug trial failure and then tries to refill its pipeline by licensing a product created by another firm, such a “rushed innovation” is less likely to bring a product to market than one developed under normal, less hurried conditions. That’s because the hastily drawn licensing agreement between the two organizations leads to friction that drags development work to a halt.

University of Kentucky Researcher Leads First Human Study of Drug Targeting Brain Inflammation

A study examining MW189 in healthy adult volunteers was performed by a collaborative team from the University of Kentucky, Duke University and Northwestern University. The work by Van Eldik and the rest of the team is substantial as it is the first time MW189 had been tested in humans.

Aversion to Risk by R&D Managers May Hurt U.S. Economic Prospects

While concerns loom over an impending recession caused by the spread of COVID-19, policymakers and business leaders have implemented radical strategies, such as slashing interest rates to invigorate the U.S.’s weakened economy. Research and Development (R&D) has long been key in the nation’s economic prospects and according to new research from the University of California San Diego, the country’s ability to maintain its competitive edge in this area largely depends on managers in R&D being less averse to risk.

Harrington Discovery Institute at University Hospitals Opens Call for 2021 Harrington Scholar-Innovator Award

An announcement that the Harrington Discovery Institute at University Hospitals is accepting letters of intent for the 2021 Harrington Scholar-Innovator Award. The award offers inventive physician-scientists resources and expertise to advance their discoveries into medicines.

Major Asian Gene Study to Help Doctors Battle Disease

“Under-representation of Asian populations in genetic studies has meant that medical relevance for more than half of the human population is reduced,” one researcher said.

Closing of Second Antibiotic Company Highlights Urgent Need for Investment in Infection Fighting Drugs

The bankruptcy announced today by antibiotic maker Melinta once again highlights the daunting challenges facing research and development of new infection-fighting drugs. Melinta is the second antibiotic company this year forced into bankruptcy because it could not make a sufficient return on its investment in medicines that are urgently needed to protect individual and public health and national security. Melinta’s bankruptcy puts into jeopardy the continued availability of its four antibiotics — lifesaving tools that patients cannot afford to lose given our already limited antibiotic arsenal.

IU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery center

The IU-led center is one of only two multi-institution teams in the nation selected as part of a new federal program intended to improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline.

Getting New Medical Treatments to Patients Can be Harder Than Landing on Mars

It takes about 10 years and $100 million to get a new medical device to market – $1 billion for a new drug. Most new solutions fail. The biggest foils are not the science or pre-clinical trials but the lack of finances, market miscalculation, bad business models, and regulatory snags. They can all be overcome.